Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05874193 | A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma(COSTA) | withdrawn | Phase 2 | 0 | Cristiana Costa Chase, DOOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07297160 | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors(CALySSEY) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Sep 16, 2026 |
| NCT04579523 | ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07428369 | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)(LINKER-MM8) | withdrawn | Phase 2 / Phase 3 | 0 | Regeneron PharmaceuticalsINDUSTRY | 0 | Jun 18, 2026 | clinicaltrials |
| NCT06348147 | Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07195617 | Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment(r/r MM) | withdrawn | N/A | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 0 | May 28, 2026 | clinicaltrials |
| NCT07082270 | Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06698744 | UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | David WaldOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05846737 | BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT | withdrawn | Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07071909 | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04398680 | A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function(DREAMM 13) | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 3 | Dec 4, 2025 | clinicaltrials |
| NCT02315157 | Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | withdrawn | Phase 2 | 0 | Situs Cancer Research CenterOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06352866 | Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM | withdrawn | Phase 2 | 0 | Jack Khouri, MDOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06411301 | A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors(AcTRESS) | withdrawn | Phase 1 | 0 | Jules Bordet InstituteOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06050512 | Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | Kathleen DorritieOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT02298816 | B-Cell Hematologic Malignancy Vaccination Registry(HMvax-Regist) | withdrawn | — | 0 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT03000634 | 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 0 | Sep 5, 2024 | clinicaltrials |
| NCT05050305 | Marizomib Central Nervous System (CNS) | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05820763 | Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 10, 2024 | clinicaltrials |
| NCT05204160 | Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06232707 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ALUMMINATE) | withdrawn | Phase 3 | 0 | CelgeneINDUSTRY | 27 | May 31, 2024 | clinicaltrials |
| NCT06400264 | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 6, 2024 | clinicaltrials |
| NCT05950113 | CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT04685525 | Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT05013437 | Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma(AHCT) | withdrawn | Early Phase 1 | 0 | Koen van BesienOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04466475 | Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05980507 | An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04864522 | Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma(MM FPBMC) | withdrawn | Phase 1 / Phase 2 | 0 | University of VirginiaOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT05647512 | Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases | withdrawn | Phase 1 / Phase 2 | 0 | LaNova Medicines LimitedINDUSTRY | 0 | Nov 18, 2023 | clinicaltrials |
| NCT05321862 | Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.(PENTI-MIDAS) | withdrawn | Phase 2 | 0 | Nantes University HospitalOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT03701321 | Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT04258683 | A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE | withdrawn | Phase 2 | 0 | Canadian Myeloma Research GroupOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT03591614 | Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma | withdrawn | Early Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05918250 | mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | withdrawn | Phase 1 | 0 | ModernaTX, Inc.INDUSTRY | 2 | Aug 18, 2023 | clinicaltrials |
| NCT04348006 | Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients(MM) | withdrawn | Phase 4 | 0 | Al-Rasheed University CollegeOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05393999 | SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations(SABRE) | withdrawn | Phase 2 | 0 | Imperial College Healthcare NHS TrustOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | withdrawn | Phase 1 | 0 | Shanghai Pudong HospitalOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05362331 | Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy | withdrawn | N/A | 0 | University of California, San FranciscoOTHER | 0 | Feb 9, 2023 | clinicaltrials |
| NCT05408026 | Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM | withdrawn | Phase 1 / Phase 2 | 0 | Alliance Foundation Trials, LLC.OTHER | 0 | Jan 27, 2023 | clinicaltrials |
| NCT05493618 | Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. | withdrawn | Phase 1 / Phase 2 | 0 | Hackensack Meridian HealthOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02389543 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients(SLAM) | withdrawn | Phase 1 / Phase 2 | 0 | Karyopharm Therapeutics IncINDUSTRY | 0 | Jan 26, 2023 | clinicaltrials |
| NCT02628704 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma(SCORE) | withdrawn | Phase 2 | 0 | Karyopharm Therapeutics IncINDUSTRY | 1 | Jan 26, 2023 | clinicaltrials |
| NCT00995059 | Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 5, 2023 | clinicaltrials |
| NCT04223661 | Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy | withdrawn | Phase 2 | 0 | Attaya SuvannasankhaOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT04998747 | A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ProxiMMity-1) | withdrawn | Phase 1 | 0 | AmgenINDUSTRY | 0 | Sep 27, 2022 | clinicaltrials |
| NCT04802031 | Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | Thomas Martin, MDOTHER | 0 | Jul 7, 2022 | clinicaltrials |
| NCT04467281 | A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Jul 1, 2022 | clinicaltrials |
| NCT03841565 | Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 15, 2022 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials